Predictive Technology Group, Inc. (PRED) Finalizes Acquisition of ReNovo Biotech, Inc.

Company Seeks to Expand Its Current Portfolio with ReNovo’s Stem and Tissue Products

Salt Lake City, UT — (April 12, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), announces that the Company has completed its acquisition of ReNovo Biotech, Inc., establishing a new wholly-owned subsidiary called Predictive Biotech, Inc.

The acquisition provides PRED access to ReNovo Biotech’s cellular, tissue, biomaterial and regenerative medicine products and product candidates. Also, PRED will gain access to ReNovo’s distribution channels, including access to customers from a recent signing of a private label agreement.  ReNovo has additional private label agreements pending for future implementations.

As part of PRED’s acquisition and restructuring, ReNovo Biotech’s CEO Eric Olson has been appointed as the President of Predictive Biotech, Inc.

Bradley Robinson, CEO of Predictive Technology Group, Inc., said, “We are very excited to announce that we have completed our due diligence, and have now been able to finalize our acquisition of ReNovo Biotech. This acquisition is a significant milestone for PRED and is the first step in our strategy to expand our product portfolio of technologies that are companion treatment solutions to our molecular diagnostic tests and pharmaceuticals. It will quickly help bring our company into revenue and cash flow through the existing distribution channels and private label partnerships. This allows us to begin clinical trials on the treatment of debilitating diseases with allogeneic and autologous stem cell products.”

Mr. Robinson continues, “Eric Olson is a proven President and CEO with over 20 years of experience in a broad range of various stage companies. Mr. Olson has established an outstanding record of verifiable success exceeding revenue, profit and business growth objectives in the rapidly changing medical device, biologics, and molecular diagnostic industries. He has experience in taking companies public and commercializing new technologies. Most recently, Mr. Olson was the President and CEO of Skeletal Kinetics in Cupertino, CA, and before that the President and CEO of Amedica Corporation in Salt Lake City, Utah.”

PRED continues on its commercialization expansion of novel therapeutics both through internal growths and acquisition of complementary diagnostic and therapeutic companies.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases effectively, and

About ReNovo Biotech, Inc.

ReNovo Biotech, Inc. is a cellular and regenerative medicine company, focused on the development, processing and distribution of innovative allograft tissues, stem cells and biomaterials for the treatment of serious and debilitating diseases. The company develops and acquires technologies that incorporate the use of genome sequencing with proprietary tissue/stem cell recovery to ensure the highest quality treatment options for its surgeon customers and their patients.

For further information contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090,

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.


Virginia Beach, VA- April 7, 2016- Element Global, Inc. (OTCPINK:ELGL) announces that its management team successfully negotiated a “Letter of Intent” on a pending acquisition of an international corporation.

After 15-months of negotiations between Global Holdings, Inc., Element Global, Inc. and this international corporation, all parties involved agreed to finalize a “Letter of Intent” on an acquisition.  Element Global, Inc. will acquire the international corporation’s assets and operations.   These assets are more than €3B (three billion) Euros.

Element Global, Inc. committed an enormous of amount of time and resources in working through this agreement.

As more news becomes available on this pending acquisition, more information about this agreement will be posted in a timely fashion.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, at 757-306-6090 and

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.


Toronto, Ontario- April 6 2016- Goldland Holding Co. (OTCPINK: GHDC) announces that on April 7, 2016at 9:30 AM ET, the Corporation will trade under its new name Bravo Multinational Incorporated, its new stock symbol BRVO (OTCPINK:BRVO), and its CUSIP number is 10568F109.

The Company’s management is proud to hold this new Company flag (BRVO) as a symbol that represents the true goals, commitments, and directives which have been mapped out over the past several months. Except for unforeseen timing issues, the mandates set in-play have shaped into a solid foundation on which to grow this company to new heights.

Please be patient if this FINRA “Corporate Action” is not updated immediately on certain web quote mediums. Some stock quote websites can take a few days to update their servers to recognize the symbol, BRVO.

All shareholders will receive a Company letter outlining the current changes and the effects it may have on some shareholders.  Shareholders holding shares in broker accounts will not be affected as this process is handled internally. Instructions to all shareholders that possess shares in “CERTIFICATE” form are outlined within this letter, stating that these certificates must be surrendered to the Company for verification of proper issuance as per current stringent standards of brokers and clearing houses.  When submitting certificates for conversion, holders MUST provide to the Company ALL documentation which verifies to management significant proof of legal ownership and proper issuance, including but not limited to all contracts, and other official documentation. Upon proper verification, new issuances will be made.

The Company can not provide any supporting documentation on existing outstanding certificates.

Currently there are approximately 167,000,000 shares that are in certificate form. Of those, there are approximately 100,000,000 shares that are under administrative “Stop Transfer Orders.”

In the very near term, BRVO will make an application to OTCMARKETS.COM to uplift to the OTCQB trading platform.

A new website is under development, and other corporate information will be forthcoming when available.

For further information about Bravo Multinational Incorporated contact, Kara Craig, YES INTERNATIONAL, 757-306-6090, and

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCPINK: BRVO) is a diversified Company, holding casino equipment in South America and gold / silver mining properties in North America. BRVO’s growth strategy, driven by mergers, acquisitions, and new ventures should result in multi-divisional, financially viable and profitable wholly-owned subsidiaries.

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.